| [15] |
胡胜, 裴永恩, 竺永健, 等. 甲状腺癌颅骨转移2例报告[J]. 中国临床神经外科杂志, 2003, 8(2): 123.
|
| [16] |
王永, 翟华明. 甲状腺癌颅骨转移1例[J]. 中国现代医生, 2009, 47(34): 109.
|
| [17] |
张晋冀, 薛峰, 蔡芾, 等. 隐匿性甲状腺癌并颅骨转移1例[J]. 大连医科大学学报, 2010, 32(5): 611-612.
|
| [18] |
姬广辉. 甲状腺癌颅骨单发转移1例报告[J]. 现代肿瘤医学, 2014, 22(12): 2991-2992.
|
| [1] |
Zaydfudim V, Feurer ID, Griffin MR, et al. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma[J]. Surgery, 2008, 144(6): 1070-1077.
|
| [2] |
Vogrin A, Besic H, Besic N, et al. Recurrence rate in regional lymph nodes in 737 patients with follicular or Hürthle cell neoplasms[J]. Radiol Oncol, 2016, 50(3): 269-273.
|
| [3] |
Sobrinho-Simões M, Eloy C, Magalhães J, et al. Follicular thyroid carcinoma[J]. Mod Pathol, 2011, 24(Suppl 2): S10-S18.
|
| [4] |
罗赛．阿克曼外科病理学[M]．8版. 沈阳：辽宁教育出版社, 1999: 528.
|
| [5] |
邱华辉, 蒋峰, 王汉盆, 等. 甲状腺癌颅骨转移2例报告[C]// 2011年浙江省神经外科学学术年会论文集, 嘉兴, 2011: 183-184.
|
| [6] |
吴江华, 丁婷婷, 潘毅, 等. 以远处转移为首发表现的24例甲状腺滤泡癌临床病理特征分析[J]. 中国肿瘤临床, 2016, 43(13): 552-556.
|
| [7] |
Hoang JK, Lee WK, Lee M, et al. US features of thyroid malignancy: pearls and pitfalls[J]. Radiographics, 2007, 27(3): 847-860.
|
| [8] |
Jeh SK, Jung SL, Kim BS, et al. Evaluating the degree of conformity of papillary carcinoma and follicular carcinoma to the reported ultrasonographic findings of malignant thyroid tumor[J]. Korean J Radiol, 2007, 8(3): 192-197.
|
| [9] |
殷德涛, 唐艺峰. 甲状腺滤泡癌的诊断和治疗热点[J]. 西安交通大学学报(医学版), 2019, 40(3): 339-342, 351.
|
| [10] |
Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma[J]. J Clin Endocrinol Metab, 2003, 88(5): 2318-2326.
|
| [11] |
Ardhaoui H, Halily S, Elkrimi Z, et al. Thyroid papillary carcinoma with an insular component metastasizing to the sella turcica and sphenoid sinus: case report[J]. Int Surg Case Rep, 2020, 67: 254-257.
|
| [12] |
Sabra MM, Dominguez JM, Grewal RK, et al. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases[J]. J Clin Endocrinol Metab, 2013, 98(5): E829-E836.
|
| [13] |
Sabra MM, Ghossein R, Tuttle RM. Time course and predictors of structural disease progression in pulmonary metastases arising from follicular cell-derived thyroid cancer[J]. Thyroid, 2016, 26(4): 518-524.
|
| [14] |
Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 2 trial[J]. Lancet Oncol, 2012, 13(9): 897-905.
|